Literature DB >> 9112032

Functional utility and oncologic safety of near-total laryngectomy with tracheopharyngeal speech shunt in a Third World oncologic center.

A M Shenoy1, P K Plinkert, N Nanjundappa, S Premalata, G R Arunodhay.   

Abstract

This prospective study analyzes the feasibility, oncologic safety and functional utility of Pearson's near-total laryngectomy with tracheopharyngeal shunt (NTL-TPSS). The procedure was found to give gratifying locoregional control in 30 consecutive advanced T3 and selected T4 tumors involving the larynx (n = 11) and hypopharynx (n = 19) and managed at Kidwai Memorial Institute of Oncology, Bangalore, India. The oncologic "safety" of this technique was established in following examinations, ranging from 18 to 44 months (median, 22.2 months). A locoregional control rate of 74% was obtained. Lung-powered "shunt" speech was acquired with ease in periods ranging from 7 days in speakers deemed "excellent" (15/29) to 20 days in those deemed "satisfactory" (8/29). Except for a single case experiencing temporary aspiration of liquids, patients did not have any swallowing difficulties following removal of nasogastric tubes. The period of hospitalization averaged 22.6 days. The complication rate was 33%, with one patient death (3.3%) occurring. The dynamics of the TPSS were analyzed in selected "speakers" and "non-speakers", using transcutaneous needle electromyography. Analysis of data supports the possibility of dynamic speech modulation. However, the favored anatomic location and design renders the shunts aspiration-proof rather than demonstrating any active sphincteric action.

Entities:  

Mesh:

Year:  1997        PMID: 9112032     DOI: 10.1007/bf02471275

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  8 in total

1.  Carcinoma of the hypopharynx.

Authors:  J P Shah; A R Shaha; R H Spiro; E W Strong
Journal:  Am J Surg       Date:  1976-10       Impact factor: 2.565

2.  Utility of near-total laryngectomy for supraglottic, pharyngeal, base-of-tongue, and other cancers.

Authors:  L W DeSanto; B W Pearson; K D Olsen
Journal:  Ann Otol Rhinol Laryngol       Date:  1989-01       Impact factor: 1.547

3.  Management of stage T3 and T4 glottic carcinomas.

Authors:  A Yuen; J E Medina; H Goepfert; G Fletcher
Journal:  Am J Surg       Date:  1984-10       Impact factor: 2.565

4.  Suitability of near-total laryngopharyngectomy in piriform carcinoma.

Authors:  P S Dumich; B W Pearson; L H Weiland
Journal:  Arch Otolaryngol       Date:  1984-10

5.  Voice preservation and restoration in advanced laryngopharyngeal cancer--the northwestern experience.

Authors:  G A Sisson; Y P Krespi
Journal:  J Laryngol Otol Suppl       Date:  1983

6.  Pearson near-total laryngectomy: a reproducible speaking shunt.

Authors:  P A Levine; R F Debo; J F Reibel
Journal:  Head Neck       Date:  1994 Jul-Aug       Impact factor: 3.147

7.  Laryngeal carcinoma--modifications in surgical technique based on an understanding of tumor growth characteristics.

Authors:  A W van Nostrand; I Brodarec
Journal:  J Otolaryngol       Date:  1982-06

8.  Carcinoma of the pyriform sinus. An analysis of treatment results and patterns of failure.

Authors:  J E Marks; B Kurnik; W E Powers; J H Ogura
Journal:  Cancer       Date:  1978-03       Impact factor: 6.860

  8 in total
  3 in total

1.  Functional laryngeal surgery - critical determinants of successful rehabilitation.

Authors:  A M Shenoy; M N Harindra; B S Premalatha; S Subbaiah; D S Reddy; A V Hari Prasad; R S
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2000-10

2.  Near total laryngectomy: the problems influencing functions and their solutions.

Authors:  Hamdi Cakli; Erkan Ozudogru; Emre Cingi; Cem Kecik; Kezban Gürbüz
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-03-05       Impact factor: 2.503

3.  [Ultrastructural changes in human nasal mucosa in rhinitis medicamentosa].

Authors:  S Knipping; H J Holzhausen; A Riederer; M Bloching
Journal:  HNO       Date:  2006-10       Impact factor: 1.284

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.